Trasylol Lawsuit News | Aprotinin Heart Surgery Drugs Renal Failure
Kidney or Aprotinin renal failure problems are among the most common problems that can be
found among the patients who have undergone a bypass surgery and were given Trasylol (aprotinin). The January 2006 New England Journal of Medicine study found that the use of aprotinin was associated with a doubling in the risk of renal failure requiring dialysis among patients undergoing complex coronary-artery surgery. Patients and families have continued to file a Trasylol lawsuit based on the failure of the manufacturer to warn about this dangerous heart surgery drug.
In the beginning, kidney failure may be asymptomatic. As kidney function decreases, symptoms result that are related to the inability to regulate water and electrolyte balances, to clear waste products from the body, and to promote red blood cell production. Lethargy, weakness, shortness of breath and generalized swelling may occur. If unrecognized or left untreated, life-threatening circumstances can develop. Renal dysfunction will require a regular dialysis in order for the patient to survive. Dialysis helps the body by performing the functions of the failed kidneys by cleansing the body of waste products in the body by use of a filter system via hemodialysis or peritoneal dialysis. Hemodialysis uses a special type of filter to remove excess waste products and water from the body. Peritoneal dialysis uses a fluid that is placed into the patient's stomach cavity through a special plastic tube to remove excess waste products and fluid from the body.
According to the 2006 Trasylol study, it is estimated that by replacing aprotinin with aminocaproic acid, it would prevent renal failure requiring dialysis in 11,050 patients per year, yielding an indirect savings (from the saved cost of dialysis) of more than $1 billion per year, in addition to direct savings (from reduced drug costs) of nearly $250 million per year. The replacement of aprotinin with tranexamic acid would prevent 9,790 complications necessitating dialysis each year, yielding similar direct and indirect savings.
We represent all Aprotinin heart surgery patients and families on a contingency basis which means that there are never any legal fees unless we win compensation in your case through a settlement or through Trasylol lawsuit. For a free no-obligation consultation please call toll free at 1-888-343-5375 or fill out our short online contact form and a Trasylol attorney will contact you to answer any of your questions.
Three antifibrinolytic agents have been used in cardiac surgery to minimize bleeding and reduce the need for transfusion. Antifibrinolytic drugs help slow the breakdown of blood clots and subsequent excessive bleeding. The first,
over its heart surgery drug which is also referred to as “Aprotinin”. The Trasylol lawsuits allege that Bayer is liable for manufacturing and failing to warn Trasylol users of its dangerous side effects. The
surgery drug has increasingly been associated with serious side effects including kidney failure and stroke following bypass surgery. Many patients and families have questioned whether Bayer’s heart drug, also referred to as “
Patients and families throughout the United States have looked at filing .jpg)

Following reports linking Bayer’s bypass surgery drug to an increased risk of Trasylol Stroke, heart attack and kidney failure the manufacturer suspended marketing the drug in late 2007. However Trasylol continued to be used until as late as May 2008 when Bayer then started removing the remaining stock from the marketplace in the United States. Trasylol is also referred to by its generic name “Aprotinin”. The FDA announced what was essentially a
families have been coming forward and filing